title: Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors.
abstract: OBJECTIVE
  Claudin proteins represent a large family of integral membrane proteins crucial for tight junction (TJ) formation and function and are abnormally regulated in several human cancers. The aim of the present study was to study the expression levels of claudin-5 in pre-malignant disease as borderline mucinous ovarian tumors. Previous reports have suggested that claudin-5 over-expression correlates with aggressive behaviour in serous ovarian adenocarcinoma, breast cancer and in pancreatic andenocarcinoma.
  
  
  METHODS
  We investigated the expression of claudin-5 in mucinous ovarian borderline tumors and its correlation with clinico-pathological parameters and the expression of serum markers cancer antigen (CA) 125 and tumor-associated trypsin inhibitor (TATI).
  
  
  RESULTS
  A total of 29 mucinous borderline tumor tissue samples were analyzed using immunohistochemical staining for claudin-5. An association between strong claudin-5 expression and higher serum levels of TATI (p=0.04) and CA125 (p=0.008) were found. There was also an association between claudin-5 expression and the presence of ascites (p=0.02).
  
  
  CONCLUSIONS
  Changes in claudin-5 expression may play a role in malignant transformation.
authors: Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland ritva-kaarina.nissi@ouka.fi.
authors: Ritva
authors: R
authors: Nissi
authors: Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
authors: Anne
authors: A
authors: Talvensaari-Mattila
authors: Department of Anatomy and Cell Biology, Institute of Biomedicine, University of Oulu, Oulu, Finland Department of Pathology, Institute of Diagnostics, Oulu University Hospital, Oulu, Finland.
authors: Paula
authors: P
authors: Kuvaja
authors: Department of Pathology, Institute of Diagnostics, Oulu University Hospital, Oulu, Finland.
authors: Paavo
authors: P
authors: Pääkkö
authors: Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, School of Medicine, University of Eastern Finland, Cancer Center of Eastern Finland, Kuopio, Finland.
authors: Ylermi
authors: Y
authors: Soini
authors: Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
authors: Markku
authors: M
authors: Santala
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000378:metabolism*; D062507:Claudin-5 / Q000502:physiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism*; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000378:metabolism*; D055815:Young Adult
chemical_list: D018394:CA-125 Antigen; C107466:CLDN5 protein, human; D062507:Claudin-5; D014359:Trypsin Inhibitor, Kazal Pancreatic
keywords: CA 125; TATI; claudin; ovarian mucinous borderline tumor